Treatment of Allergic Rhinitis With Desloratadine: Results of a Multinational Observational Study in the Middle East Gulf Region

World Allergy Organization Journal

Tamer MH Adham¹ 

[1] Faculty of Medicine, Ain Shams University, Egypt, Al Noor Hospital, Abu Dhabi, United Arab Emirates

关键词: peak nasal inspiratory flow;    nasal congestion;    Middle East;    desloratadine;    allergic rhinitis;   

Others  :  1145589
DOI  :  10.1097/WOX.0b013e31822a6e9a

【 摘 要 】

Background

Allergic rhinitis (AR) affects up to 36% of the population in the Middle East Gulf States. The second-generation nonsedating antihistamine desloratadine has demonstrated safety and efficacy in the treatment of AR; however, few studies have evaluated this agent in Arab and Asian populations in the Middle East.

Methods

This open-label study enrolled subjects ≥ 12 years with moderate-to-severe AR; they received desloratadine 5 mg QD for 2 weeks. Endpoints included change in mean individual nasal and ocular symptom scores, total symptom score (TSS), and peak nasal inspiratory flow (PNIF) and percentage improvement in global response to therapy.

Results

There were 602 subjects from 5 Middle East countries enrolled. After 2 weeks, desloratadine significantly (P < 0.0001) reduced mean scores for individual nasal and total ocular symptom scores and TSS. PNIF measures of nasal congestion were significantly (P < 0.0001) improved after treatment. Most subjects obtained complete (38.1%) or marked (47.2%) relief of AR symptoms. Treatment failure was reported in 2.2% of subjects. No adverse events were reported, and no subjects discontinued treatment.

Conclusion

Most subjects reported significant symptom relief with desloratadine 5 mg/d for 2 weeks. Desloratadine is effective in the treatment of AR in Arab and Asian subjects in the Middle East Gulf region.

【 授权许可】

   
2011 World Allergy Organization; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Alsowaidi S, Abdulle A, Shehab A, Zuberbier T, Bernsen R: Allergic rhinitis: prevalence and possible risk factors in a Gulf Arab population. Allergy 2010, 65:208-212.
• [2]Owayed A, Behbehani N, Al-Momen J: Changing prevalence of asthma and allergic diseases among Kuwaiti children. An ISAAC Study (Phase III). Med Princ Pract 2008, 17:284-289.
• [3]Janahi IA, Bener A, Bush A: Prevalence of asthma among Qatari schoolchildren: International Study of Asthma and Allergies in Childhood, Qatar. Pediatr Pulmonol 2006, 41:80-86.
• [4]Behbehani N, Arifhodzic N, Al-Mousawi M, Marafie S, Ashkanani L, Moussa M, Al-Duwaisan A: The seasonal variation in allergic rhinitis and its correlation with outdoor allergens in Kuwait. Int Arch Allergy Immunol 2004, 133:164-167.
• [5]Lestringant G-G, Bener A, Frossard P-M, Abdulkhalik S, Bouix G: A clinical study of airborne allergens in the United Arab Emirates. Allerg Immunol (Paris) 1999, 31:263-267.
• [6]Sattar HA, Mobayed H, Al-Mohammed AA, Ibrahim AS, Jufairi AA, et al.: The pattern of indoor and outdoor respiratory allergens in asthmatic adult patients in a humid and desert newly developed country. Eur Ann Allergy Clin Immunol 2003, 35:300-305.
• [7]Ezeamuzie CI, Al-Ali S, Khan M, et al.: IgE-mediated sensitization to mould allergens among patients with allergic respiratory diseases in a desert environment. Int Arch Allergy Immunol 2000, 121:300-307.
• [8]Blaiss MS, Meltzer EO, Derebery MJ, Boyle JM: Patient and healthcare-provider perspectives on the burden of allergic rhinitis. Allergy Asthma Proc 2007, 28(Suppl 1):S4-S10.
• [9]Shedden A: Impact of nasal congestion on quality of life and work productivity in allergic rhinitis. Findings from a large online survey. Treat Respir Med 2005, 4:439-446.
• [10]Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F: Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000, 162:1391-1396.
• [11]Meltzer EO, Nathan R, Derebery J, Stang PE, Campbell UB, et al.: Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 2009, 30:244-254.
• [12]Sih T, Mion O: Allergic rhinitis in the child and associated comorbidities. Educational Clinical Case Series. Pediatr Allergy Immunol 2009, 21:e107-e113.
• [13]Stull D, Roberts L, Frank L, Heithoff K: Relationship of nasal congestion with sleep, mood, and productivity. Current Med Res Opin 2007, 23:811-819.
• [14]Young T, Fin L, Kim H, The University of Wisconsin Sleep and Respiratory Research Group: Nasal obstruction as a risk factor for sleep-disordered breathing. J Allergy Clin Immunol 1997, 99:S757-S762.
• [15]Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A: Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007, 120:381-387.
• [16]Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, et al.: Allergic rhinitis and its impact on asthma (ARIA) 2008 update in collaboration with the World Health organization, GA2LEN, and Aller-Gen. Allergy 2008, 63(Suppl 86):8-160.
• [17]Aerius [summary of prescribing characteristics] Brussels, Belgium: Schering-Plough Europe Ltd; 2010.
• [18]Bousquet J, Bachert C, Canonica GW, Mullol J, van Cauwenberge P, The ACCEPT-2 study group, et al.: Efficacy of desloratadine in persistent allergic rhinitis: a GA2LEN study. Int Arch Allergy Immunol 2010, 153:395-402.
• [19]Bousquet J, Bachert C, Canonica GW, Mullol J, van Cauwenberge P, The ACCEPT-1 study group, et al.: Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study. Allergy 2009, 64:1516-1523.
• [20]Holmberg K, Tonnel AB, Dreyfus I, Olsson P, Cougnard J, Mesbah K, Devillier P: Desloratadine relieves nasal congestion and improves quality of life in persistent allergic rhinitis. Allergy 2009, 64:1663-1670.
• [21]Bachert C, van Cauwenberge P: Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Clin Ther 2007, 29:1795-1802.
• [22]Kim K, Sussman G, Hébert J, Lumry W, Lutsky B, Gates D: Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2006, 96:460-465.
• [23]Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG: Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006, 96:363-368.
• [24]Simons FER, Prenner BM, Finn A Jr, The Desloratadine Study Group: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003, 111:617-622.
• [25]Nayak AS, Schenkel E: Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001, 56:1077-1080.
• [26]Aberer W: Desloratadine for the relief of nasal and non-nasal allergic symptoms: an observational study. Arch Drug Inf 2009. doi:10.1111/j (.1753-5174.2009):00018.x
• [27]Mendoza de Morales T, Sanchez F: Clinical efficacy and safety of a combined loratadine-betamethasone oral solution in the treatment of severe pediatric perennial allergic rhinitis. World Allergy Organ J 2009, 2:49-53.
• [28]Tassinari P, Suárez NR, Centeno J, Velásquez J, Aguirre-Mariscal H, The LA Desloratadine Study Group, et al.: Desloratadine therapy improves allergic rhinitis symptoms in Latin American children aged 6 to 12 years. World Allergy Organ J 2009, 2:42-48.
• [29]Kaulsay R, Rampal S, Puraviappan P: Effectiveness of desloratadine in improving quality of life in patients with persistent allergic rhinitis. Paper presented at 26th Congress of the European Academy of Allergy and Clinical Immunology (EAACI); June 9-13, 2007; Göteburg, Sweden
• [30]Ciebiada M, Gorska-Ciebiada M, Gorski P: The safety and efficacy of desloratadine for the treatment of perennial allergic rhinitis: a multicenter study in Poland. Ann Allergy Asthma Immunol 2008, 100(S1):A91.
• [31]Dumitrascu D: Improved symptom relief and quality of life with desloratadine in pollen-induced allergic rhinitis. J Allergy Clin Immunol 2007, 119(Suppl):S64.
• [32]Braverman I, Beiser M, Gilad Z: Desloratadine treatment improves symptoms in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 119(Suppl):S64.
• [33]Kósa L: A multicenter, open-label study of desloratadine for the treatment of nasal and ocular symptoms of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2008, 121:S51.
• [34]Montagne M: Desloratadine is safe and effective in the treatment of nasal symptoms of persistent allergic rhinitis (PAR): results of two observational studies. J Allergy Clin Immunol 2006, S320:1236.
• [35]Carvalho A, Brito U, Cunha J, Torres S, Duarte P, Pereira D: The effect of 4-week treatment with desloratadine 5 milligrams once daily on quality of life and nasal symptoms in subjects with perennial allergic rhinitis and asthma. J Allergy Clin Immunol 2009, 123:S135.
• [36]Villafuerte CV, Almazan NA, Joson RE: Desloratadine 5 milligrams daily is safe, well tolerated, and effective in subjects in the Philippines with allergic rhinitis or chronic idiopathic urticaria. Allergy 2009, 64(Suppl 90):S593.
• [37]Jawad J, Abdelmotaal A, Al-Nawasany O, Gamal A, Tahmeh H, et al.: Observational study evaluating nighttime and early morning treatment satisfaction in patients receiving once daily desloratadine for seasonal allergic rhinitis in routine daily practice in Saudi Arabia. Allergy 2008, 63(Suppl 88):S523.
• [38]Canonica GW, Tarantini F, Compalati E, Penagos M: Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 2007, 62:359-366.
• [39]Demoly P, Dreyfus I, Dhivert-Donnadieu H, Mesbah K: Desloratadine for the treatment of cypress pollen-induced allergic rhinitis. Ann Allergy Asthma Immunol 2009, 103:260-266.
• [40]Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Allen M, Marseglia GL: Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005, 5:1800-1808.
• [41]Wilson AM, Haggart K, Sims EJ, Lipworth BJ: Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002, 32:1504-1509.
• [42]Berger WE, Lumry WR, Meltzer EO, Pearlman DS: Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006, 27:214-223.
• [43]Horak F, Stübner P, Zieglmeyer R, Harris AG: Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003, 58:481-485.
• [44]Berger WE, Schenkel EJ, Mansfield LE: Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002, 89:485-491.
• [45]Greiff L, Persson CG, Andersson M: Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002, 89:413-418.
• [46]Horak F, Stubner UP, Zieglmayer R, Harris AG: Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002, 109:956-961.
• [47]Meltzer EO, Prenner BM, Nayak A, The Desloratadine Study Group: and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons. Clin Drug Invest 2001, 21:25-32.